Market Cap 657.23M
Revenue (ttm) 0.00
Net Income (ttm) -247.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.14
Volume 2,188,800
Avg Vol 5,830,136
Day's Range N/A - N/A
Shares Out 78.06M
Stochastic %K 75%
Beta 0.42
Analysts Sell
Price Target $10.43

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 222 9600
Address:
500 Unicorn Park Drive, Suite 303, Woburn, United States
LineBacker04
LineBacker04 Oct. 25 at 12:39 AM
$CAPR Part-3 4. And finally...PUL 2.0 did pass the initial futility analysis - which means the study monitors were noticing a difference at 3 months - which is expected to broaden at 12 months. The other aspect is what happens if PUL 2.0 is a marginal miss? For me in this situation, the expectation is that they will be able to respond to the CRL with LVEF "additional data" and restart the BLA. It will result in a narrower label, but it will likely lead to an approval. From what I'm told, there's language in the type-A meeting minutes talking about "regulatory flexibility" - and I expect this to show up just like it did for $REPL earlier this month. The reason for this is not just a change of heart for Dr. Vinay Prasad - its a situation where he's feeling the pressure from multiple sources and he needs to demonstrate this "flexibility" just to stay on the job. I'm also told that in this scenario - $CAPR will not only PR the results, but till also PR their intent to respond to the CRL.
5 · Reply
Smellmahass
Smellmahass Oct. 24 at 10:35 PM
$AQST This and $REPL My medium long term. Pdufas always run up. Almost risk free investement. As the catalysts is the pdufa which usually come at the last week.
0 · Reply
BiotechDrTrader
BiotechDrTrader Oct. 24 at 10:09 PM
$REPL for anyone saying adcom would be a bad thing for replimune, ur smoking it, given the massive support from oncologists any adcom would support approval for sure and be a positive
2 · Reply
Julie25
Julie25 Oct. 24 at 9:42 PM
$REPL Not going to be approved. AdComm will reject it before FDA does. RUN.
0 · Reply
BiotechDrTrader
BiotechDrTrader Oct. 24 at 8:03 PM
$REPL What happened to all the shorts? They all quiet now that price has stabilized - I continue to think that now that vinay prasad has had his near death experience being fired and coming back, he's decided that it's not worth his political career to reject good drugs like replimune for stupid reasons, like wanting a non-ethical control arm. He wanted to treat checkpoint progressors with more checkpoints lol, when all the literature says its pointless. Oh and after the FDA already agreed the study design was fine previously. I think he will quietly approve REPL this time around and move on with his life.
2 · Reply
UnicornProfits
UnicornProfits Oct. 24 at 7:57 PM
If you missed those runs on $ARTV $REPL $NTRP $CIIT Don't miss ticker CMCT !! CMCT has only 728k shares float and is the next squeeze! Looks like shorts got trapped below and now CMCT is squeezing up!!
0 · Reply
Main_Street_Risks
Main_Street_Risks Oct. 24 at 7:24 PM
$REPL Thoughts on resubmission. They come out of meeting and say they have not determined path forward for accelerated approval, then fast forward couple weeks and we have an accepted BLA and Pdufa of April 10th? So they took about 3 weeks to make resubmission (resubmitted Oct 10). What did they decide between Sep and Oct 10th? Likely to take the higher risk/ fastest option which includes addressing the FDA comments (with new data cuts/analysis) but not fully addressing the issue (no new trial). What should be clear is this path is not a clear path to accelerated approval or they would have said so. The best they did was say the FDA considers it a complete response…which actually just means they answered every question, inherent to the BLA acceptance. This is likely the only decent option for them. Create hope. Raise more funds and buy time. There really isn’t a legitimate alternative if FDA is willing to take another look without a new trial.
1 · Reply
Smellmahass
Smellmahass Oct. 24 at 10:43 AM
$REPL Whats likelihood this will get an adcom comittee?
2 · Reply
BiotechDrTrader
BiotechDrTrader Oct. 23 at 7:02 PM
$REPL Just a reminder that the majority of oncologists world wide were expecting REPL to be approved the first time based on the exceptional data, and now vinay prasad has the chance to fix his error while saving face by pointing to additional data submitted by the company. I bet it gets approved several months prior to PDUFA since FDA already familiar with the submission ... :) https://www.linkedin.com/posts/kevin-harrington-013b4b3b_letter-to-office-of-the-commissioner-usfda-activity-7356063520137875457-6DGa/?utm_source=share&utm_medium=member_ios&rcm=ACoAAC2z7UcBrMA01Zg-q3xZNgm4J15ou08OD2Y
2 · Reply
Bonanza2252003
Bonanza2252003 Oct. 23 at 6:17 PM
$REPL Don’t fight it baggies . It’s just not going to get worse tomorrow 🤣
0 · Reply
Latest News on REPL
Replimune Provides Update Following Type A Meeting with FDA

Sep 18, 2025, 9:15 AM EDT - 5 weeks ago

Replimune Provides Update Following Type A Meeting with FDA


Replimune Announces Type A Meeting Scheduled with FDA

Sep 2, 2025, 8:00 AM EDT - 7 weeks ago

Replimune Announces Type A Meeting Scheduled with FDA


Replimune Group: The Prospects For FDA Approval After Rejection

Aug 7, 2025, 10:08 AM EDT - 2 months ago

Replimune Group: The Prospects For FDA Approval After Rejection


Why Is Replimune Stock Trading Lower On Monday?

Aug 4, 2025, 12:43 PM EDT - 2 months ago

Why Is Replimune Stock Trading Lower On Monday?


Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

May 22, 2025, 11:19 AM EDT - 5 months ago

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript


Replimune: A Misunderstood Contender In Oncolytics

Feb 12, 2025, 4:21 PM EST - 9 months ago

Replimune: A Misunderstood Contender In Oncolytics


LineBacker04
LineBacker04 Oct. 25 at 12:39 AM
$CAPR Part-3 4. And finally...PUL 2.0 did pass the initial futility analysis - which means the study monitors were noticing a difference at 3 months - which is expected to broaden at 12 months. The other aspect is what happens if PUL 2.0 is a marginal miss? For me in this situation, the expectation is that they will be able to respond to the CRL with LVEF "additional data" and restart the BLA. It will result in a narrower label, but it will likely lead to an approval. From what I'm told, there's language in the type-A meeting minutes talking about "regulatory flexibility" - and I expect this to show up just like it did for $REPL earlier this month. The reason for this is not just a change of heart for Dr. Vinay Prasad - its a situation where he's feeling the pressure from multiple sources and he needs to demonstrate this "flexibility" just to stay on the job. I'm also told that in this scenario - $CAPR will not only PR the results, but till also PR their intent to respond to the CRL.
5 · Reply
Smellmahass
Smellmahass Oct. 24 at 10:35 PM
$AQST This and $REPL My medium long term. Pdufas always run up. Almost risk free investement. As the catalysts is the pdufa which usually come at the last week.
0 · Reply
BiotechDrTrader
BiotechDrTrader Oct. 24 at 10:09 PM
$REPL for anyone saying adcom would be a bad thing for replimune, ur smoking it, given the massive support from oncologists any adcom would support approval for sure and be a positive
2 · Reply
Julie25
Julie25 Oct. 24 at 9:42 PM
$REPL Not going to be approved. AdComm will reject it before FDA does. RUN.
0 · Reply
BiotechDrTrader
BiotechDrTrader Oct. 24 at 8:03 PM
$REPL What happened to all the shorts? They all quiet now that price has stabilized - I continue to think that now that vinay prasad has had his near death experience being fired and coming back, he's decided that it's not worth his political career to reject good drugs like replimune for stupid reasons, like wanting a non-ethical control arm. He wanted to treat checkpoint progressors with more checkpoints lol, when all the literature says its pointless. Oh and after the FDA already agreed the study design was fine previously. I think he will quietly approve REPL this time around and move on with his life.
2 · Reply
UnicornProfits
UnicornProfits Oct. 24 at 7:57 PM
If you missed those runs on $ARTV $REPL $NTRP $CIIT Don't miss ticker CMCT !! CMCT has only 728k shares float and is the next squeeze! Looks like shorts got trapped below and now CMCT is squeezing up!!
0 · Reply
Main_Street_Risks
Main_Street_Risks Oct. 24 at 7:24 PM
$REPL Thoughts on resubmission. They come out of meeting and say they have not determined path forward for accelerated approval, then fast forward couple weeks and we have an accepted BLA and Pdufa of April 10th? So they took about 3 weeks to make resubmission (resubmitted Oct 10). What did they decide between Sep and Oct 10th? Likely to take the higher risk/ fastest option which includes addressing the FDA comments (with new data cuts/analysis) but not fully addressing the issue (no new trial). What should be clear is this path is not a clear path to accelerated approval or they would have said so. The best they did was say the FDA considers it a complete response…which actually just means they answered every question, inherent to the BLA acceptance. This is likely the only decent option for them. Create hope. Raise more funds and buy time. There really isn’t a legitimate alternative if FDA is willing to take another look without a new trial.
1 · Reply
Smellmahass
Smellmahass Oct. 24 at 10:43 AM
$REPL Whats likelihood this will get an adcom comittee?
2 · Reply
BiotechDrTrader
BiotechDrTrader Oct. 23 at 7:02 PM
$REPL Just a reminder that the majority of oncologists world wide were expecting REPL to be approved the first time based on the exceptional data, and now vinay prasad has the chance to fix his error while saving face by pointing to additional data submitted by the company. I bet it gets approved several months prior to PDUFA since FDA already familiar with the submission ... :) https://www.linkedin.com/posts/kevin-harrington-013b4b3b_letter-to-office-of-the-commissioner-usfda-activity-7356063520137875457-6DGa/?utm_source=share&utm_medium=member_ios&rcm=ACoAAC2z7UcBrMA01Zg-q3xZNgm4J15ou08OD2Y
2 · Reply
Bonanza2252003
Bonanza2252003 Oct. 23 at 6:17 PM
$REPL Don’t fight it baggies . It’s just not going to get worse tomorrow 🤣
0 · Reply
BiotechDrTrader
BiotechDrTrader Oct. 23 at 5:59 PM
$REPL $REPL it’s so annoying how X is flooded with spam for replimune, those bots are the worst…
0 · Reply
Bonanza2252003
Bonanza2252003 Oct. 23 at 2:51 PM
$REPL Looks like we caught some more bagholders today 🤣
0 · Reply
ProfessorGamma
ProfessorGamma Oct. 22 at 11:01 PM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $MLTX $COKE $REPL $MNTS Watchlist,
0 · Reply
BiotechDrTrader
BiotechDrTrader Oct. 22 at 8:14 PM
$REPL awww are the shorts crying today? Trying to cover? sad to see
1 · Reply
Alidrisi
Alidrisi Oct. 22 at 8:05 PM
0 · Reply
BiotechDrTrader
BiotechDrTrader Oct. 22 at 7:48 PM
$REPL Just FYI, FDA said the additional data and analyses included in the most recent re-submission addresses the CRL (the CRL was stupid in the first place, asking for a control arm when it would be unethical to do so and was already agreed on earlier that it wasn't needed), so now they will obviously adjudicate on it, but I have a good feeling this time around it will be approved. Vinay Prasad saw his life flash before his eyes when the sarepta patient outcry caused him to get ousted and then brought back in, and he's noticeably backed off from sarepta. He's also not saying anything negative about the tylenol / autism idiocy coming from the current administration. He will choose the easier path and approve REPL this time around. ALSO, FDA approvals can happen months prior to PDUFA dates, and theres been a trend of early approvals recently. Since they are already familiar with the data, I think theres a good chance FDA approval happens earlier than the stated PDUFA date. Bullish!
2 · Reply
Bonanza2252003
Bonanza2252003 Oct. 22 at 5:29 PM
$REPL Just stopping by to remind you , sub $5 by Friday 🤣💪
2 · Reply
MKRReformed
MKRReformed Oct. 22 at 4:33 PM
$REPL $VKTX 1) there actually isn’t any analysis, but rather bragging about calls I already got right. 2) I am almost assuredly a better trader than you, as I am 99%+ of people as evidenced by easily crushing the market for three straight years since going full time, being in the top 5000 on tip ranks, and literally getting audited due to an abnormally high RoI. Time is in Buenos Aires time (where I’ve functionally retired in my early 30s) and all Index %s are accurate within the past day or two due to there being update lag on the actual websites It’s ok to be insecure, especially if you’re losing money on both these plays that I’ve had very good rois on shorting, but it’s really not my responsibility to coddle your ignorance. I’m well within the top 1% of traders in the world, all while maintaining very tight risk management. Gain some self awareness and some money scrub
1 · Reply
biolover
biolover Oct. 22 at 3:51 PM
$REPL $VKTX idiot analysis
0 · Reply
MKRReformed
MKRReformed Oct. 22 at 3:30 PM
$REPL 9 puts now up 200% if held, common share short up 22% from $10. Bear side paying big $VKTX 32.5p now up 85% from entry. Cashing out and switching to 30p in .70s To survive this type of market you have to play both ways
2 · Reply
Maddmike
Maddmike Oct. 22 at 2:56 PM
0 · Reply
Gj64
Gj64 Oct. 22 at 2:28 PM
$REPL https://www.stocktitan.net/news/GRTX/galera-therapeutics-announces-acquisition-of-dismutase-mimetics-8pulrnbo7s22.html
0 · Reply